Transcript
Page 1: 120 B167 Improved Cryopreservation & Recovery Solutions ...tools.thermofisher.com/content/sfs/posters/ASCB_2013_Poster.pdf · •Prototypes will be available in Jan. 2014. Please

0

20

40

60

80

100

120

0 20 40 60 80 100 120 140

Time Post-Split (Hours)

0

20

40

60

80

100

120

0 20 40 60 80 100 120 140

Essential 8TM Alone

+ Post-Thaw Recovery

Supplement

Essential 8TM Alone

David T. Kuninger, Lauren E. Sangenario, and Rhonda A. Newman, Cell Biology & Stem Cell Sciences, Life Technologies, Frederick, MD 21704

RESULTS

• mFreSRTM was shown to be “Best-in-Class”

• While several commercial cryopreservation solutions provide high

viability (>70%) post-thaw, these measurements are overestimates of

effective iPSC survival, as cell death from apoptosis and necrosis

following cryopreservation can take days to be realized [1-2].

• Viability 24 hours post-thaw is predictive of post-thaw recovery

•There was shown to be significant room for improvement

Figure 2. Experimental Workflow for Optimizing PSC Cryomedium

• Process workflows were used in optimization of cryomedium and

recovery medium solutions

• Assays fit for purpose were determined and used in development of

reagents using a series of screens, iterative DOEs, and titrations

• Our improved xeno-free cryomedium coupled with chemically defined post-

thaw recovery supplement provides optimum post-thaw recovery of iPSCs

• When used together with the chemically defined post-thaw supplement

being applied for 18-24 hours post passaging at each passage, iPSCs are

shown to maintain normal morphology, pluripotency, and karyotype

• Use of the post-thaw recovery supplement in conjunction with various

cryomedia provides significant improvement over the use of traditional ROCK

inhibitor, Y-27632

ABSTRACT

Pluripotent stem cells (PSCs) and primary cells are foundational tools

for basic research and applied applications including regenerative

therapy, drug discovery, and toxicological assessment. While stem

cells have a tremendous proliferative capacity, long term culture of

these cells has been shown to cause an accumulation of mutations

that result in genetic instability, increasing tumorigenicity and thus

limiting their usefulness in research and clinical applications.

Improved solutions for cryopreservation of early passage cells that

minimize loss of viability, maximize post-thaw recovery, and minimize

unwanted differentiation are essential components to PSC, as well as

primary cell workflows. While many cryopreservation reagents afford

high viability immediately post-thaw, significant apoptosis and

necrosis is often observed following the first 24 hours post-thaw,

decreasing the effective viability, reducing cell numbers and adding

additional stress and selective pressure to cultures. Further, this

extends the time post-thaw cells must be cultured prior to use in

downstream experiments. Using a series of Design of Experiments

(DOEs) and mathematical modeling methods, we describe the

development of a xeno-free cryomedium for use in cryopreservation

of PSCs and ESCs, and a chemically defined post-thaw recovery

supplement for use in recovery of PSCs, ESCs, as well as difficult-to-

preserve primary cells. When used together, we show this system

provides >80% direct post-thaw viability of PSCs with >70% cell

survival following 24 hours post-plating. As a result of increased post-

thaw survival rate, cells recover faster and are ready to passage

sooner than with current solutions, while maintaining pluripotency and

normal karyotype over 10 passages. Additionally, the post-thaw

recovery supplement was tested in combination with other

cryopreservation reagents which lead to markedly improved 24 hour

post-thaw viability of difficult-to-preserve primary cells, including

primary cortical neurons, human corneal epithelial cells, and human

epidermal keratinocytes.

INTRODUCTION

The goals of this research were (1) to provide improved, cost-effective

solutions for cryopreservation and recovery of PSCs, (2) identify

applicability of solutions to additional difficult-to-preserve cell types,

as well as, (3) assess alternative applications for the developed post-

thaw recovery supplement.

Life Technologies currently offers two ready-to-use cryopreservation

media: Synth-a-Freeze and RecoveryTM Cell Culture Freezing

Medium. During our development, these media were tested for their

applicability for cryopreservation of PSCs in comparison with the

currently recommended protocol of use of Essential 8TM + 10%

DMSO, as well as optimized solutions.

Six Sigma Design Excellence principles were used to guide

generation of improved cryopreservation and recovery systems with

an initial focus on the PSC workflow. Broader applicability of

solutions to primary cell types was subsequently assessed and is still

underway.

CONCLUSIONS• MSAs were used to define assays fit for purpose for determining cryomedia

which maximize post-thaw viability & recovery

•DOEs and mathematical modeling were used to improve Life Technologies’

solutions and associated protocols for cryopreservation and recovery of

PSCs

• Additional utility of post-thaw recovery supplement is demonstrated for

recovery of additional cryopreserved cell types, as well as for single cell

passaging of PSCs

• Prototypes will be available in Jan. 2014. Please contact Rhonda Newman

([email protected]) or Wendy Bray ([email protected])

for more information. For Research Use Only. Not for diagnostic purposes.

REFERENCES1. Baust JM, Vogel MJ, VanBuskirk RG, and Baust JG. A Molecular Basis of

Cryopreservation Failure and its Modulation to Improve Cell Survival. Cell

Transplantation (2001) 10:561-571

2. Baust JM, VanBuskirk RG, Baust JG. Cell viability improves following

inhibition of cryopreservation-induced apoptosis. In Vitro Cell. Dev. Biol.

Anim. (2000) 36(4):262-270

ACKNOWLEDGEMENTSWe would like to thank Rene Quintanilla, Tori Barron, Marian Piekarczyk,

Connie Lebakken, David Piper, Alexandria Sams, Kirsten Amaral, Stephen

Ferguson for helpful discussions.

TRADEMARKS/LICENSING© 2013 Life Technologies Corporation. All rights reserved. The trademarks mentioned

herein are the property of Life Technologies Corporation and/or its affiliate(s) or their

respective owners. mFreSR is a trademark of StemCell Technologies, Inc. Essential 8 is a

registered trademark of Cellular Dynamics International, Inc. pZerve is a trademark of

Protide Pharmaceuticals, Inc. Stem-CellBanker is a registered trademark of Nippon

Zenyaku Kogyo Co., Ltd. hESFreeze is a trademark of GlobalStem. Accutase is a

registered trademark of Innovative Cell Technologies.

Improved Cryopreservation & Recovery Solutions for

Pluripotent Stem Cells & Difficult-to-Preserve Primary Cells

Life Technologies • 5791 Van Allen Way • Carlsbad, CA 92008 • www.lifetechnologies.com

B167

A. Input-Output Control Diagram for Cryomedium Development

B. Process Workflow for Cryomedium & Recovery Medium Development

0

25

50

75

100

%S

YT

OX

AA

Dva

nce

dT

M

Neg

ati

ve

17

23

29

35

41

47

53

59

66

72

78

84

90

%Viability

Each Pair

Student’s t

0.05

BL3 Sytox AADvanced 640-H

Co

un

t

Assessment of Direct Post-Thaw Viability

200,000

Pre

sto

Blu

e

Flu

ore

sc

en

ce

400,000

600,000

800,000

9

11

16

22

27

33

38

43

49

54

59

65

70

%Viability

Each Pair

Student’s t

0.05

76

82

Assessment of 24 Hour Post-Thaw Viability

Determined Assays Fit for

Purpose By Screening

Various Cell Health

Reagents for Accurate

Discrimination of

Differences in Cell Viability

Conducted Iterative DOEs

to Determine Reagnets with

the Largest Impact on Cell

Viability

Conducted Small Molecule

Library Screens to Identify

Prosurvival Small Molecules

Compared Optimum

Formulations w/ Commercial

& Homebrew Solutions

Assessed

Commercial

Solutions Using

Assays Fit for

Purpose

Control

Factors

Cryopreservation

of Feeder-Free

PSCs

Critical

Functional

Responses

Noise

Factors

1. Basal Medium

2. Cryoprotective Agents A. Type

B. Concentration

3. Medium Additives

A. Membrane Stabilizers

B. Caspase Inhibitors

C. Antioxidants

D. Non-permeating solutes

4. Freezing Protocol

A. Temperature of

Cryopreservation Medium

B. Time of exposure prior to

freezing

C. Freezing Rate

1. Donor Variability

2. Size of Stem Cell clusters

3. Chemical Impurities

in Reagents

1. Post-Thaw Viability

2. Post-Thaw Recovery

3. Maintenance of Normal

Pluripotency

4. Maintenance of Normal

Karyotype

Final Formulation(s)

Assessment of

Post-Thaw

Viability (Direct & 24 Hour)

Assessment of

Post-Thaw Recovery

Maintenance of Normal

Karyotype & Pluripotency

C. Defining Assays Fit for Purpose

D. Example DOE Used in Optimization of Post-Thaw Recovery

Figure 3. Analysis of Existing Cryomedium Solutions for induced PSC (iPSC)

Cryopreservation

A. Direct Post-Thaw Viability

Re

co

ve

ryT

M C

ell

Cu

ltu

re F

ree

zin

g M

ed

ium

E8

+ 1

0%

DM

SO

Syn

th-a

-Fre

eze

®

Cry

oS

tor5

Cry

oS

tor1

0

hE

SF

ree

ze

mF

reS

RT

M

pZ

erv

eT

M

Ste

m-

Ce

llB

an

ke

All Pairs

Tukey-Kramer

0.05

0

25

50

75

100

%S

yto

xA

AD

va

nc

ed

TM

Ne

ga

tive

B. 24 hours Post-Thaw Viability

1,000,000

Pre

sto

Blu

e

Flu

ore

sc

en

ce

2,000,000

3,000,000

4,000,000

Re

co

ve

ryT

M C

ell

Cu

ltu

re F

ree

zin

g M

ed

ium

E8

+ 1

0%

DM

SO

Syn

th-a

-Fre

eze

®

Cry

oS

tor5

Cry

oS

tor1

0

hE

SF

ree

ze

TM

mF

reS

RT

M

pZ

erv

eT

M

Ste

m-

Ce

llB

an

ke

r® All Pairs

Tukey-Kramer

0.05

E8 +

10% DMSO

Synth-a-

Freeze® CryoStor10

pZerve

Stem-

CellBanker®

CryoStor5RecoveryTM

hESFreezeTM mFreSRTM

LIV

E/D

EA

Re

pre

se

nta

tive

Im

ag

es

C. Post-Thaw Recovery

(Confluence Monitored 6 Days Post-Thaw)

0

Inc

uC

yte

TM

Mo

nit

ore

d C

on

flu

en

ce

Re

co

ve

ryT

M C

ell

Fre

ezin

g M

ed

ium

E8

+ 1

0%

DM

SO

Syn

th-a

-Fre

eze

®

Cry

oS

tor5

Cry

oS

tor1

0

hE

SF

ree

ze

TM

mF

reS

RT

M

pZ

erv

eT

M

Ste

m-

Ce

llB

an

ke

All Pairs

Tukey-Kramer

0.05

20

40

60

80

100

D. Maintenance of PluripotencyEssential 8TM +

10% DMSO Synth-a-Freeze®

Alk

ali

ne

Ph

os

ph

ata

se

Liv

e S

tain

Oc

t-4/

-tu

bu

lin

SS

EA

4/N

uc

Blu

e

mFreSRTM

E8 + 10% DMSO;

E8 +10 µM Y-27632

FBS + 10% DMSO;

E8 +10 µM Y-27632

mFreSRTM; E8 +

10 µM Y-27632

PSC Cryomedium;

E8 + Post-Thaw Recovery

Supplement

Figure 4. iPSC Cryopreservation and Recovery Using Optimized Solutions

A. Optimized Cryomedium & Post-Thaw Recovery Solutions Provide Maximum Recovery of

Cryopreserved iPSCs

D. Post-Thaw Recovery Supplement Can

Improve Recovery of iPSCs Cryopreserved

in Multiple Cryomedia Solutions

Pre

sto

Blu

e

Flu

ore

sc

en

ce

(24

Ho

urs

Po

st-

Th

aw

)

IncuCyte ZOOM Phase Contrast

Images w/ Confluence Mask

Pre

sto

Blu

e

Flu

ore

sc

en

ce

(24

Ho

urs

Po

st-

Th

aw

)

B. Optimized Solutions Provide

Efficient Post-Thaw Recovery of iPSCs

0

20

40

60

80

100

0 50 100 150 200

Essential 8 Alone

Essential 8 + Post-Thaw Recovery Supplement

Inc

uC

yte

TM

Mo

nit

ore

d C

on

flu

en

ce

Time Post-Thaw (Hours)

C. Optimized Solutions Provide Maintenance of

Normal Morphology, Pluripotency, & Karyotype of

iPSCs Over 10 Passages Post-Thaw

Figure 5. Post-Thaw Recovery Supplement Demonstrates Applicability for

Recovery of Cryopreserved Primary Cells

Calcein/EthD-1

Calc

ein

Ob

ject

Co

un

t/

Eth

D-1

Ob

ject

Co

un

t

Cell Body/Neurite

A. Experimental Workflow

B. HEKn 24 Hour Post-Thaw Viability

C. HCEC 24 Hour Post-Thaw Viability

Pre

sto

Blu

e

Flu

ore

sc

en

ce

(24 H

ou

rs P

ost-

Th

aw

)

Pre

sto

Blu

e

Flu

ore

sc

en

ce

(24 H

ou

rs P

ost-

Th

aw

)

Quickly Thawed

Cryopreserved

Cells at 37 °C

Performed Viable

Cell Counts

Plated at

Recommended

Seeding Densities in

Growth Medium +/-

post-thaw recovery

supplement

Incubated Cells at

37 °C, 5% CO2

for 24 Hours

Assessed Viability 24

Hours Post-Thaw

Using PrestoBlue

Cell Viability Reagent

OR LIVE/DEAD

Viability/Cytotoxicity

Kit

Fed Neurons According to

Recommended Protocol

w/ Growth Medium

Lacking post-thaw

recovery supplement

6 Days Post-

Thaw Assessed

Neurite LengthOR

D. Rat Cortical Neuron 24 Hour Post-Thaw Viability

E. Rat Cortical Neuron Neurite Length

(6 Days Post-Thaw)

Ca

lce

in/E

thD

-1

Ob

ject

Co

un

tN

eu

rite

Len

gth

(mm

/[C

ell B

od

y C

luste

r]

Figure 6. Post-Thaw Recovery Supplement Demonstrates Applicability for

Survival of PSCs Following Single Cell Passaging

• Our chemically defined post-thaw recovery

supplement shows utility in recovery from

cryopreservation of a variety of primary cell

types, including human epidermal

keratinocytes, neonatal (HEKn), human

corneal epithelial cells (HCECs), and rat

cortical neurons

A. StemPro Accutase Passaged iPSC Recovery

Time Post-Split (Hours)

B. TrypLETM Select Passaged iPSC Recovery

Inc

uC

yte

Mo

nit

ore

d

%C

on

flu

en

ce

)

• Use of the Post-Thaw Recovery Supplement for 18-24 hours post-single

cell passaging via StemPro Accutase or TrypLE TMSelect passaging

provides vast improvement of cell survival compared to recovery in

Essential 8TM Alone

• Multi passage study is currently underway using single cell passaging

Essential 8TM Alone

+ Post-Thaw Recovery

Supplement

Essential 8TM Alone

Figure 1. Life Technologies Provides a Broad Array

of Solutions for Pluripotent Stem Cell Research

Culture Reprogram Characterize Expand Cryopreserve Differentiate Measure

CytoTuneTM

Lentiviral iPSC

Reprogramming

Particles

KnockOutTM

ESC/iPSC Media

Kit

KnockOutTM

CTS XenoFree

ESC/iPSC Media

Kit

Gibco® Primary

Cell MediaAlkaline

Phosphatase

Live Stain

ELF® 97

Endogenous

Phosphatase

Detection Kit

Conjugated

Antibodies (e.g.,

anti-TRA-1-60 &

anti-SSEA4)

TaqMan® Stem

Cell Pluripotency

Array

KnockOutTM

ESC/iPSC Media

Kit

KnockOutTM

CTS XenoFree

ESC/iPSC Media

Kit

StemPro® hESC

SFM

StemPro® Differentiation

Kits

Human

Recombinant

Growth Factors

(e.g., BMP-4,

bFGF, DKK-1,

Noggin)

TaqMan® Ready

Made Probes

Primary &

Secondary

Antibodies for

Immunocytoche

mistry

Goal

Cryopreservation

of PSCs

Pre

sto

Blu

eA

ctu

al

PrestoBlue Predicted

Inc

uC

yte

Mo

nit

ore

d

%C

on

flu

en

ce

)

E8 + Post-Thaw Recovery

Supplement 24 Hour Recovery

3 Hours 24 Hours

48 Hours 72 Hours

96 Hours 120 Hours

E8 + Post-Thaw Recovery

Supplement 24 Hour Recovery

3 Hours 24 Hours

48 Hours 72 Hours

96 Hours 120 Hours

IncuCyte ZOOM Phase Contrast

Images w/ Confluence Mask

Phase Oct4

NanogTra1-60

Karyotype

Recommended